M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

被引：1
|
作者：
Lockmer, Sandra [1 ,2 ]
Ren, Weicheng [3 ]
Ostenstad, Bjorn [4 ]
Brodtkorb, Marianne [5 ]
Wahlin, Bjorn E. [6 ,7 ,8 ]
Pan-Hammarstrom, Qiang [9 ]
Kimby, Eva [10 ]
机构：
[1] Karolinska Inst, Dept Internal Med, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[3] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden
[4] Oslo Univ Hosp, Oslo, Norway
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden
[7] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[8] Karolinska Univ Hosp, Stockholm, Sweden
[9] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden
[10] Karolinska Inst, Hematol, Stockholm, Sweden
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117949
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4154
引用
收藏
页数：3
相关论文
共 50 条
  • [1] M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy
    Lockmer, Sandra
    Ren, Weicheng
    Brodtkorb, Marianne
    Ostenstad, Bjorn
    Wahlin, Bjoern E.
    Pan-Hammarstrom, Qiang
    Kimby, Eva
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (02) : 259 - 267
  • [2] The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
    Kimby, Eva
    Lockmer, Sandra
    Holte, Harald
    Hagberg, Hans
    Wahlin, Bjorn E.
    Brown, Peter
    Ostenstad, Bjorn
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (05) : 738 - 747
  • [3] A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy
    Vindi, Jurinovic
    Kridel, Robert
    Staiger, Annette M.
    Szczepanowski, Monika
    Horn, Heike
    Dreyling, Martin H.
    Rosenwald, Andreas
    Ott, German
    Klapper, Wolfram
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    Ansell, Stephen
    Sehn, Laurie H.
    Connors, Joseph M.
    Gascoyne, Randy D.
    Weinstock, David M.
    Hiddemann, Wolfgang
    Unterhalt, Michael
    Hoster, Eva
    Weigert, Oliver
    BLOOD, 2015, 126 (23)
  • [4] SINGLE AGENT RITUXIMAB IS A VALID OPTION FOR FIRST-LINE TREATMENT IN FOLLICULAR LYMPHOMA
    Ghielmini, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 81 - 81
  • [5] Rituximab As First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular Lymphoma
    Croxtall, Jamie D.
    DRUGS, 2011, 71 (07) : 885 - 895
  • [6] Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens
    Soo, Joanne
    Scherer, Florian
    Kurtz, David M.
    Schroers-Martin, Joseph G.
    Jin, Michael
    Craig, Alexander
    Stehr, Henning
    Liu, Chih Long
    Green, Michael R.
    Weigert, Oliver
    Diehn, Maximilian
    Alizadeh, Ash A.
    BLOOD, 2017, 130
  • [7] Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
    Zucca, Emanuele
    Rondeau, Stephanie
    Vanazzi, Anna
    Ostenstad, Bjorn
    Mey, Ulrich J. M.
    Rauch, Daniel
    Wahlin, Bjorn E.
    Hitz, Felicitas
    Hernberg, Micaela
    Johansson, Ann-Sofie
    Brown, Peter de Nully
    Hagberg, Hans
    Ferreri, Andres J. M.
    Lohri, Andreas
    Novak, Urban
    Zander, Thilo
    Bersvendsen, Hanne
    Bargetzi, Mario
    Mingrone, Walter
    Krasniqi, Fatime
    Dirnhofer, Stefan
    Hayoz, Stefanie
    Hawle, Hanne
    Vilei, Simona Berardi
    Ghielmini, Michele
    Kimby, Eva
    Caspar, Clemens
    Koberle, Dieter
    Novak, Urban
    Zenhausern, Reinhard
    Jost, Lorenz M.
    Mach, Nicolas
    Voegeli, Michele
    Tscherry, Georg
    Fischer, Natalie
    Burkhard, Roger
    Schmid, Mathias
    Panagiotis, Samaras
    Munksgaard, Lars
    Hernberg, Micaela
    Vasala, Kaija
    Lehtinen, Tuula
    Jyrkkio, Sirkku
    Ekanger, Roald
    Rolke, Jurgen
    Meyer, Peter
    Maisenholder, Martin
    Eidem, Monika
    Radlund, Anders
    Lagerlof, Ingemar
    BLOOD, 2019, 134 (04) : 353 - 362
  • [8] Rituximab Maintenance Therapy After First-Line induction Chemoimmunotherapy for Follicular Lymphoma
    Hilal, Talal
    Leis, Jose F.
    Reeder, Craig B.
    JAMA ONCOLOGY, 2018, 4 (06) : 859 - 860
  • [9] First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
    Urso, Antonio
    Cavazzini, Francesco
    Ballardini, Maria Pia
    Gambara, Silvia
    Consolo, Sara
    Rigolin, Gian Matteo
    Cuneo, Antonio
    CANCERS, 2023, 15 (15)
  • [10] Rituximab as First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular Lymphoma Profile Report
    Croxtall, Jamie D.
    BIODRUGS, 2011, 25 (05) : 329 - 331
12345